LQ 043H
Alternative Names: Inhaled TSLP Nanobody; LQ-043H; LQ043Latest Information Update: 11 Sep 2023
At a glance
- Originator Shanghai Novamab Biopharmaceuticals
- Class Antiasthmatics; Monoclonal antibodies; Single-domain antibodies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 19 May 2023 Preclinical trials in Asthma in China (Inhalation) prior to May 2023
- 19 May 2023 Pharmacodynamics, safety and pharmacokinetic data from a preclinical studies in Pneumonia presented at the 119th International Conference of the American Thoracic Society, 2023 (ATS-2023)
- 19 May 2023 Phase-I clinical trials in Asthma in China (Inhalation) prior to May 2023